288242
Mature driver laws and state predictors of motor vehicle crash fatality rates among the elderly
Methods: We modeled state MVC fatality rates for the population over age 65 as a function of state transportation policies, demographic, health system, population health, travel, and climate characteristics using a general linear model. Because death due to motor vehicle crash is a rare outcome among the elderly, we aggregated vital statistics data from 2006-2010 to ensure stability of rate estimates. Principal component analysis was used to reduce dimensionality of the data and overcome multicollinearity of state predictor variables.
Results: Average temperature, gas price, and ratio of emergency medicine physicians to population size were significant negative predictors of MVC fatality rates. Positive predictors were percent of population overweight or obese and percent with college degree over the age of 65. Having any restriction on elderly drivers was associated with a higher MVC fatality rate and no individual component of mature driver laws significantly decreased fatality rates.
Conclusions: Mature driver laws are not associated with lower MVC fatality rates among the elderly.
Learning Areas:
Public health or related laws, regulations, standards, or guidelinesPublic health or related public policy
Learning Objectives:
Evaluate the impact of mature driver laws on state motor vehicle crash fatality rates among the elderly.
Keyword(s): Policy/Policy Development, Motor Vehicles
Qualified on the content I am responsible for because: I am a PhD candidate in Health Outcomes and Policy Research at the University of TN Health Science Center and have taken over 70 credit hours of coursework relating to statistics and health policy. I have been active in research for the past 9 years. My research has focused on injury, health disparities, and spatial determinants of health outcomes for the past 3 years.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.